Table 2.

Extracted nanomedicine entities

Class	Entity
Nanomedicine description	Company
	FDA approval date
	Trade name
	US patent
Nanoparticle physicochemical characterization	Active ingredient
	Core composition
	Molecular weight
	Nanoparticle
	Particle diameter
	Surface coating
Exposure	Dose
	Route of administration
Pharmacokinetics	AUC
	Clearance
	Cmax
	Elimination half-life
	Plasma half-life
	Tmax
	Volume of distribution
Biologic response	Adverse reaction
	Indication

Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; FDA, US Food and Drug Administration; Tmax, time to reach Cmax.